FDA to Authorize Pfizer, Merck's COVID-19 Pills

The US Food and Drug Administration (FDA) will authorize two COVID-19 Treatment Pills from Pfizer and Merck on Wednesday, Reuters cited Blomberg.

Both treatments showed promising results, and they helped in preventing severe COVID-19 symptoms, and deaths.

The clinical trials also expressed that Merck succeeded in reducing the risk of Coronavirus' symptoms, and related deaths by 30%, on the other hand, Pfizer showed better results with 90% in dropping COVID-19 risks.

Britain was the first country in the world to approve Merck’s treatment for mild to moderate COVID-19 cases.

Today, FDA's panel voted for Merck to pave the way to its soon approval and recommendation by the authority.

Panel member Dr. David Hardy said: "COVID-19 is still an emergency situation," adding, "There is a need for something like this. This is the first opportunity that an oral outpatient medication for mildly symptomatic to moderately symptomatic persons will be available, although I do have questions about its overall longer-term efficacy."